This brief was filed on behalf of over 200 reproductive health, rights, and justice organizations, including the Center for Reproductive Rights.

These organizations have directly seen the importance of medication abortion to individuals’ health and bodily autonomy, as well as mifepristone’s efficacy and safety as a tool for achieving those goals; have a unique window into the benefits mifepristone provides and the immense challenges people would face if the decision below takes effect; several represent abortion providers and patients and have experience litigating cases involving plaintiffs and their experts; and others are clinics or healthcare providers who would be directly impacted by the district court’s decision. The brief affirms that mifepristone is safe, effective, and widely used and that the consequences of suspending FDA’s approval of mifepristone will be immediate and severe.

This brief was one of many filed in Alliance for Hippocratic Medicine v. FDA. For more information on the case, click here.